Corvus Pharma Expects FY24 Net Cash Used In Operating Activities ~$24M-$27M, Resulting In Projected Cash Balance Of $31M-$34M At Dec. 31, 2024; Expects Cash To Find Operations Into Q4 2025
Corvus Pharma Expects FY24 Net Cash Used In Operating Activities ~$24M-$27M, Resulting In Projected Cash Balance Of $31M-$34M At Dec. 31, 2024; Expects Cash To Find Operations Into Q4 2025
Corvus Pharma預計，24財年用於經營活動的淨現金約爲2400萬至2700萬美元，預計截至2024年12月31日的現金餘額爲3100萬至3,400萬美元；預計現金將在2025年第四季度投入運營
Corvus Pharma Expects FY24 Net Cash Used In Operating Activities ~$24M-$27M, Resulting In Projected Cash Balance Of $31M-$34M At Dec. 31, 2024; Expects Cash To Find Operations Into Q4 2025
Corvus Pharma預計，24財年用於經營活動的淨現金約爲2400萬至2700萬美元，預計截至2024年12月31日的現金餘額爲3100萬至3,400萬美元；預計現金將在2025年第四季度投入運營
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。